Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
Status:
Completed
Trial end date:
2015-09-28
Target enrollment:
Participant gender:
Summary
The objective of this study is to explore the safety and the preliminary efficacy of two
concentrations (0.06% and 0.03%)gel that is applied to lesions of early stage (IA, IB,IIA)
Cutaneous T Cell Lymphoma patients.
This study is supported by grant 1R01FD004092-01A1 from the Office of Orphan Products
Development, FDA.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania